Raffles Medical Group Ltd (SGX:BSL)
Singapore · Delayed Price · Currency is SGD | Market Cap | 1.76B -8.7% |
| Revenue (ttm) | 765.57M +1.7% |
| Net Income | 70.57M +13.4% |
| EPS | 0.04 +14.1% |
| Shares Out | 1.84B |
| PE Ratio | 25.07 |
| Forward PE | 24.22 |
| Dividend | 0.03 (3.14%) |
| Ex-Dividend Date | May 12, 2026 |
| Volume | 1,116,400 |
| Average Volume | 1,583,010 |
| Open | 0.9600 |
| Previous Close | 0.9550 |
| Day's Range | 0.9550 - 0.9650 |
| 52-Week Range | 0.9400 - 1.0900 |
| Beta | 0.21 |
| RSI | 31.41 |
| Earnings Date | Jul 28, 2026 |
About Raffles Medical Group
Raffles Medical Group Ltd provides private healthcare services in Singapore, Greater China, Vietnam, Cambodia, and Japan. It operates through four segments: Healthcare Services, Hospital Services, Investment Holdings, and Insurance Services. The company operates Raffles Hospital that offers 24-hour acute and critical care; ambulance services and mobile medical calls to home, hotels, worksites, and onboard ships; and triage, emergency consultation, and inpatient ward admission services. Its hospital also provides various services, including covi... [Read more]
Financial Performance
In 2025, Raffles Medical Group's revenue was 765.57 million, an increase of 1.75% compared to the previous year's 752.43 million. Earnings were 70.57 million, an increase of 13.38%.
Financial StatementsNews
Raffles Medical Group upgraded to Buy from Neutral at Nomura
Nomura upgraded Raffles Medical Group to Buy from Neutral with an unchanged price target of S$1.60. The analyst sees the company benefiting from an increase in local and foreign patients
Raffles Medical Group upgraded to Outperform from Neutral at Credit Suisse
Credit Suisse analyst Amanda Foo upgraded Raffles Medical Group to Outperform from Neutral with a price target of S$1.80, up from S$1.30. The analyst lifted estimates to reflect the company’s